- Home
- SGML vs MLYS Comparison
SGML vs MLYS Comparison
Compare SGML & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGML
- MLYS
- Stock Information
- Founded
- SGML 2011
- MLYS 2019
- Country
- SGML Brazil
- MLYS United States
- Employees
- SGML N/A
- MLYS N/A
- Industry
- SGML Industrial Machinery/Components
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- SGML Industrials
- MLYS Health Care
- Exchange
- SGML Nasdaq
- MLYS Nasdaq
- Market Cap
- SGML 879.0M
- MLYS 1.0B
- IPO Year
- SGML N/A
- MLYS 2023
- Fundamental
- Price
- SGML $7.25
- MLYS $14.65
- Analyst Decision
- SGML Strong Buy
- MLYS Strong Buy
- Analyst Count
- SGML 2
- MLYS 3
- Target Price
- SGML $18.00
- MLYS $33.00
- AVG Volume (30 Days)
- SGML 846.9K
- MLYS 661.0K
- Earning Date
- SGML 05-14-2025
- MLYS 05-12-2025
- Dividend Yield
- SGML N/A
- MLYS N/A
- EPS Growth
- SGML N/A
- MLYS N/A
- EPS
- SGML N/A
- MLYS N/A
- Revenue
- SGML $145,080,064.00
- MLYS N/A
- Revenue This Year
- SGML $43.73
- MLYS N/A
- Revenue Next Year
- SGML $130.53
- MLYS N/A
- P/E Ratio
- SGML N/A
- MLYS N/A
- Revenue Growth
- SGML 15.18
- MLYS N/A
- 52 Week Low
- SGML $6.76
- MLYS $8.24
- 52 Week High
- SGML $19.20
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- SGML 37.35
- MLYS 53.36
- Support Level
- SGML $6.81
- MLYS $14.03
- Resistance Level
- SGML $8.40
- MLYS $15.79
- Average True Range (ATR)
- SGML 0.48
- MLYS 0.99
- MACD
- SGML 0.03
- MLYS 0.10
- Stochastic Oscillator
- SGML 25.36
- MLYS 57.57
About SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.